Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Palliation of breast carcinoma 40 mg 4 times/day. Palliation of endometrial carcinoma 40-320 mg/day in divided doses. Anorexia and cachexia in patients w/ cancer or AIDS Initial: 800 mg/day. Usual: 400-800 mg/day.
Megace ES: May be taken with or without food.
Standard formulation: Should be taken with food.
Pregnancy and lactation. Severe hepatic impairment.
Special Precautions
History of thrombophlebitis, mild to moderate hepatic impairment, risk of fluid retention, history of depression, diabetes, hypertension, renal or cardiac dysfunction.
Adverse Reactions
Acne, urticaria, fluid retention, wt gain, heart failure, nausea, vomiting, GI disturbances, changes in libido, breast discomfort, premenstrual symptoms, irregular menstrual cycles, depression, insomnia, somnolence, alopecia, hirsutism, anaphylactoid-like reaction, jaundice, hot flushes, adrenocortical suppression, carpal tunnel syndrome, hypercalcaemia, tumour flare, hypertension.
ROUTE(S) : PO: D For tablet.
ROUTE(S) : PO: X For oral suspension.
Drug Interactions
Concentrations of indinavir may be reduced. Possible reduced efficacy of cisplatin. Warfarin half life may be increased. Megestrol concentration may be decreased by aminoglutethimide and enzyme-inducing drugs.
ATC Classification
G03DB02 - megestrol ; Belongs to the class of pregnadien derivative progestogens used in progestogenic hormone preparations.
G03AC05 - megestrol ; Belongs to the class of progestogens. Used as systemic contraceptives.
L02AB01 - megestrol ; Belongs to the class of progestogens.
Disclaimer: This information is independently developed by CIMS based on megestrol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in